A two‐drug combination simulation study for metastatic castrate resistant prostate cancer

Abstract

Overall, this study finds that genetic background and tumor heterogeneity are more important than drug potency in treating mCRPC. It also points toward identifying metastatic sites early using biochemical assays and/or dPET.

Structure-based assessment and network analysis of targeting 14-3-3 proteins in prostate cancer

“…Despite these advances, 29,430 men will die of prostate cancer (PCa) in the U.S.A in 2018 [ 2 ]. A simulation study based on survival data of 2353 PCa patients concluded that a two-drug combination therapy is unlikely to cure mCRPC patients [ 3 ]. Hence, searching for higher-order drug combinations targeting pathways in addition to PI3K/AKT/mTOR is warranted.…”